HBIO — Harvard Bioscience Cashflow Statement
0.000.00%
Last trade - 00:00- $167.17m
- $199.45m
- $112.25m
- 68
- 60
- 26
- 50
Annual cashflow statement for Harvard Bioscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -4.69 | -7.81 | -0.288 | -9.52 | -3.42 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 5.36 | 5.55 | 4.45 | 0.791 | 5.51 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.042 | 4.11 | -10.2 | 2.72 | 4.6 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 8.04 | 9.33 | 1.26 | 1.15 | 14 |
| Capital Expenditures | -1.22 | -1.15 | -1.34 | -1.59 | -2.31 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.987 | -0.25 | — | — | 0.512 |
| Sale of Business | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.229 | -1.4 | -1.34 | -1.59 | -1.8 |
| Financing Cash Flow Items | -0.221 | -2.37 | -3.62 | -1.63 | -2.52 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -7.62 | -7.97 | -0.252 | -2.84 | -12.1 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.162 | -0.018 | -0.496 | -3.31 | -0.225 |